Dihydroergotamine mesylate nasal spray: an acute treatment option for migraine in adults

References

• Pescador Ruschel MA, De Jesus O. Migraine headache. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Aug 23]. https://www.ncbi.nlm.nih.gov/books/NBK560787/.
   Google Scholar
• Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol. 2017;16(1):76–87. doi: 10.1016/S1474-4422(16)30293-9
   PubMed Web of Science ®Google Scholar
• Feigin VL, Nichols E, Alam T, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18(5):459–480. doi: 10.1016/S1474-4422(18)30499-X
   PubMed Web of Science ®Google Scholar
• GBD. 2016 headache collaborators. global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the global burden of disease study 2016 [published correction appears in Lancet Neurol. 2021 Dec;20(12): e7]. Lancet Neurol. 2018;17(11):954–976. doi: 10.1016/S1474-4422(18)30322-3
   PubMedGoogle Scholar
• Steiner TJ, Stovner LJ, Jensen R, et al. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137. doi: 10.1186/s10194-020-01208-0
   PubMed Web of Science ®Google Scholar
• Sacco S, Lampl C, Amin FM, et al. European headache federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain. 2022;23(1):133. doi: 10.1186/s10194-022-01502-z
   PubMed Web of Science ®Google Scholar
• VanderPluym JH, Halker Singh RB, Urtecho M, et al. Acute treatments for episodic migraine in adults: a systematic review and meta-analysis. JAMA. 2021;325(23):2357–2369. doi: 10.1001/jama.2021.7939.
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen PC, Koehler PJ. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. Cephalalgia. 2008;28(8):877–886. doi: 10.1111/j.1468-2982.2008.01578.x
   PubMed Web of Science ®Google Scholar
• Müller-Schweinitzer E, Weidmann H. Basic pharmacologic properties. In: Berde B Schild H, editors. Ergot alkaloids and related compounds. Berlin: Springer-Verlag; 1978. p. 87–232 58.
   Google Scholar
• Shafqat R, Flores-Montanez Y, Delbono V, et al. Updated evaluation of IV dihydroergotamine (DHE) for refractory migraine: patient selection and special considerations. J Pain Res. 2020;13:859–864. doi: 10.2147/JPR.S203650
   PubMed Web of Science ®Google Scholar
• Labruijere S, Chan KY, de Vries R, et al. Dihydroergotamine and sumatriptan in isolated human coronary artery, middle meningeal artery and saphenous vein. Cephalalgia. 2015;35(2):182–189. doi: 10.1177/0333102414544977
   PubMed Web of Science ®Google Scholar
• Saper JR, Jones JM. Ergotamine tartrate dependency: features and possible mechanisms. Clin Neuropharmacol. 1986;9(3):244–256. doi: 10.1097/00002826-198606000-00003
   PubMed Web of Science ®Google Scholar
• Beau-Salinas F, Jonville-Béra AP, Cissoko H, et al. Drug dependence associated with triptans and ergot derivatives: a case/non-case study. Eur J Clin Pharmacol. 2010;66(4):413–417. doi: 10.1007/s00228-009-0769-6
   PubMed Web of Science ®Google Scholar
• Di Serio FJ.Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. dihydroergotamine nasal spray multicenter investigators. Headache. 1995;35(4):177–184. doi: 10.1111/j.1526-4610.1995.hed3504177.x
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Shrewsbury SB, Hoekman J. Dihydroergotamine (DHE) - then and now: a narrative review. Headache. 2020;60(1):40–57.
   PubMed Web of Science ®Google Scholar
• https://www.accessdata.fda.gov/drugsatfda_docs/NDA/97/020148_migranal_toc.cfm
   Google Scholar
• Tfelt-Hansen P, Saxena PR, Dahlöf C, et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain. 2000;123(1):9–18. doi: 10.1093/brain/123.1.9
   PubMed Web of Science ®Google Scholar
• Schaerlinger B, Hickel P, Etienne N, et al. Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy. Br J Pharmacol. 2003;140(2):277–284. doi: 10.1038/sj.bjp.0705437
   PubMed Web of Science ®Google Scholar
• Andersen AR, Tfelt-Hansen P, Lassen NA. The effect of ergotamine and dihydroergotamine on cerebral blood flow in man. Stroke. 1987;18:120–123. doi: 10.1161/01.STR.18.1.120
   PubMed Web of Science ®Google Scholar
• Pourshoghi A, Danesh A, Tabby DS, et al. Cerebral reactivity in migraine patients measured with functional near-infrared spectroscopy.Eur J Med Res. 2015 [cited 2015 Dec 8];20(1):96. doi: 10.1186/s40001-015-0190-9
   PubMedGoogle Scholar
• González-Hernández A, Lozano-Cuenca J, Marichal-Cancino BA, et al. Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of α2-adrenoceptors and 5-HT1 receptors. J Headache Pain. 2018 [cited 2018 May 25];19(1):40. doi: 10.1186/s10194-018-0869-8
   PubMedGoogle Scholar
• Spekker E, Tanaka M, Szabó Á, et al. Neurogenic inflammation: the participant in migraine and recent advancements in translational research.Biomedicines. 2021 [cited 2021 Dec 30];10(1):76. doi: 10.3390/biomedicines10010076
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Gundlach AL. Localization of 3H-dihydroergotaminebinding sites in the cat central nervous system: relevance to migraine. Ann Neurol. 1991;29:91–94. doi: 10.1002/ana.410290116
   PubMed Web of Science ®Google Scholar
• Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003;43(2):144–166. doi: 10.1046/j.1526-4610.2003.03034.x
   PubMed Web of Science ®Google Scholar
• Kawasaki Y, Kumamoto E, Furue H, et al. Alpha 2 adrenoceptormediated presynaptic inhibition of primary afferent glutamatergic transmission in rat substantia gelatinosa neurons. Anesthesiology. 2003;98:682–689. doi: 10.1097/00000542-200303000-00016
   PubMed Web of Science ®Google Scholar
• Willems EW, Valdivia LF, Villalon CM, et al. Possible role of alpha-adrenoceptor subtypes in acute migraine therapy. Cephalalgia. 2003;23:245–257. doi: 10.1046/j.1468-2982.2003.00547.x
   PubMed Web of Science ®Google Scholar
• Mansikka H, Erbs E, Borrelli E, et al. Influence of the dopamine D2 receptor knockout on pain-related behavior in the mouse. Brain Res. 2005;1052(1):82–87. doi: 10.1016/j.brainres.2005.06.021
   PubMed Web of Science ®Google Scholar
• Hoskin KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-fos and electrophysiological study. Brain. 1996;119(1):249–256. doi: 10.1093/brain/119.1.249
   PubMedGoogle Scholar
• Silvestro M, Tessitore A, Scotto di Clemente F, et al. Refractory migraine profile in CGRP-monoclonal antibodies scenario. Acta Neurol Scand. 2021;144(3):325–333. doi: 10.1111/ane.13472
   PubMed Web of Science ®Google Scholar
• Humbert H, Cabiac MD, Dubray C, et al. Human pharmacokinetics of dihydroergotamine administered by nasal spray. Clin Pharmacol Ther. 1996;60(3):265–275. doi: 10.1016/S0009-9236(96)90053-3
   PubMed Web of Science ®Google Scholar
• Aellig WH, Rosenthaler J. Venoconstrictor effects of dihydroergotamine after intranasal and intramuscular administration. Eur J Clin Pharmacol. 1986;30:581–584. doi: 10.1007/BF00542418
   PubMed Web of Science ®Google Scholar
• Buck M. Intravenous dihydroergotamine (DHE) for the treatment of refractory migraines. Pediatric Pharmacotherapy. 2007;13(7):1–4.
   Google Scholar
• Massiou H. Dihydroergotamine nasal spray in prevention and treatment of migraine attacks: two controlled trials versus placebo. Cephalalgia. 1987;7(suppl 6):440–441. doi: 10.1177/03331024870070S6195
   Google Scholar
• Krause K-H, Bleicher MA. Dihydroergotamine nasal spray in the treatment of migraine attacks. Cephalalgia. 1985;5(3_suppl):138–139. doi: 10.1177/03331024850050S348
   Google Scholar
• Bousser M-G. Efficacy of dihydroergotamine nasal spray in the acute treatment of migraine attacks. Cephalalgia. 1985;5(3_suppl):554–555. doi: 10.1177/03331024850050S3221
   Google Scholar
• Rohr J. Dihydroergotamine nasal spray for the treatment of migraine attacks: a comparative double-blind crossover study with placebo. Cephalalgia. 1985;5(3_suppl):142–143. doi: 10.1177/03331024850050S350
   Google Scholar
• Gallagher RM. Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine working group. Arch Neurol. 1996;53(12):1285–1291. doi: 10.1001/archneur.1996.00550120097022
   PubMedGoogle Scholar
• Ziegler D, Ford R, Kriegler J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology. 1994;44(3_part_1):447–447. doi: 10.1212/WNL.44.3_Part_1.447
   PubMed Web of Science ®Google Scholar
• Tulunay FC, Karan O, Aydin N, et al. Dihydroergotamine nasal spray during migraine attacks. A double-blind crossover study with placebo. Cephalalgia. 1987;7(2):131–133. doi: 10.1046/j.1468-2982.1987.0702131.x
   PubMed Web of Science ®Google Scholar
• Hirt D, Lataste X, Taylor P. A comparison of DHE nasal spray and Cafergot(r) in acute migraine. Cephalalgia. 1989;9(suppl 10):410–411. doi: 10.1177/0333102489009S10217
   Google Scholar
• Touchon J, Bertin L, Pilgrim AJ, et al. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology. 1996;47(2):361–365. doi: 10.1212/WNL.47.2.361
   PubMed Web of Science ®Google Scholar
• Boureau F, Kappos L, Schoenen J, et al. A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine. Int J Clin Pract. 2000;54(5):281–286. doi: 10.1111/j.1742-1241.2000.tb11905.x
   PubMed Web of Science ®Google Scholar
• Fisher M, Gosy EJ, Heary B, et al. Dihydroergotamine nasal spray for relief of refractory headache: a retrospective chart review. Curr Med Res Opin. 2007;23(4):751–755. doi: 10.1185/030079907X178883
   PubMed Web of Science ®Google Scholar
• Massiou H. Etude clinique d’un antimigraineux le Diergo-Spray, Efficacité et tolérance chez 3,396 patients. Gaz Méd. 1989;96(5):56–59.
   Google Scholar
• Jenzer G, Bremgartner MF. Dihydroergotamine as a nasal spray in the therapy of migraine attacks - efficacy and tolerance [in German]. Schweiz Rundsch Med Prax. 1990;79(31–32):914–917.
   PubMedGoogle Scholar
• Piechal A, Blecharz-Klin K, Mirowska-Guzel D. Dihydroergotamine (DHE) – is there a place for its use? J Pre Clin Clin Res. 2018;12:149–157. doi: 10.26444/jpccr/99878
   Google Scholar
• Wang VS, Kosman J, Yuan H, et al. Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: a retrospective study. Headache. 2023;63(9):1251–1258. doi: 10.1111/head.14636
   PubMed Web of Science ®Google Scholar
• Lipton RB. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Headache. 1997;37(Suppl 1):S33–S41.
   PubMed Web of Science ®Google Scholar
• Schiff PL. Ergot and its alkaloids. Am J Pharm Educ. 2006;70(5):98. doi: 10.1016/S0002-9459(24)07817-3
   PubMed Web of Science ®Google Scholar
• Albrecht D, Iwashima M, Dillon D, et al. A phase 1, randomized, open-label, safety, tolerability, and comparative bioavailability study of intranasal dihydroergotamine powder (STS101), intramuscular dihydroergotamine mesylate, and intranasal DHE mesylate spray in healthy adult subjects. Headache. 2020;60(4):701–712. doi: 10.1111/head.13737
   PubMed Web of Science ®Google Scholar
• Malaquin F, Urban T, Ostinelli J, et al. Pleural and retroperitoneal fibrosis from dihydroergotamine. N Engl J Med. 1989;321(25):1760.
   PubMed Web of Science ®Google Scholar
• Dhuria SV, Hanson LR, Frey WH. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2010 2nd;99(4):1654–1673. doi: 10.1002/jps.21924
   PubMed Web of Science ®Google Scholar
• Costantino HR, Illum L, Brandt G, et al. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm. 2007;337(1–2):1–24. doi: 10.1016/j.ijpharm.2007.03.025
   PubMed Web of Science ®Google Scholar
• Pardeshi CV, Belgamwar VS. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting. Expert Opin Drug Deliv. 2013;10(7):957–972.
   PubMed Web of Science ®Google Scholar
• Lochhead J, Thorne R. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012;64(7):614–628. doi: 10.1016/j.addr.2011.11.002
   PubMed Web of Science ®Google Scholar
• Pu Y, Goodey AP, Fang X, et al. A comparison of the deposition patterns of different nasal spray formulations using a nasal cast. Aerosol Sci Technol. 2014;48(9):930–938. doi: 10.1080/02786826.2014.931566
   Web of Science ®Google Scholar
• Silberstein S. MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine. Expert Opin Pharmacother. 2012;13(13):1961–1968. doi: 10.1517/14656566.2012.711319
   PubMed Web of Science ®Google Scholar
• Tepper SJ, Kori SH, Goadsby PJ, et al. MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments. Mayo Clin Proc. 2011;86(10):948–955. doi: 10.4065/mcp.2011.0093
   PubMed Web of Science ®Google Scholar
• Aurora S, Lu B, Connors E, et al. Analysis of subjects with menstrually related migraine vs non-menstrually related migraine treated with MAP0004. J Headache Pain. 2013;14(Suppl. 1):143. doi: 10.1186/1129-2377-14-S1-P143
   Google Scholar
• Kori S, Connors E, Zhou J, et al. Efficacy of MAP0004 in treating severe pain. J Headache Pain. 2013;14(Suppl. S1):208. doi: 10.1186/1129-2377-14-S1-P208
   Google Scholar
• Kori SH, Tepper ST, Saper J, et al. Levadex efficacy in treating resistant migraine. Ann Neurol. 2010;68:S14.
   Web of Science ®Google Scholar
• Saper JR, Silberstein S, Dodick D, et al. DHE in the pharmacotherapy of migraine: potential for a larger role. Headache. 2006;46(Suppl. 4):S212–S220. doi: 10.1111/j.1526-4610.2006.00605.x
   PubMed Web of Science ®Google Scholar
• Cooper W, Ray S, Aurora SK, et al. Delivery of dihydroergotamine mesylate to the upper nasal space for the acute treatment of migraine: technology in action. J Aerosol Med Pulm Drug Deliv. 2022;35(6):321–332. doi: 10.1089/jamp.2022.0005
   PubMed Web of Science ®Google Scholar
• Hoekman J, Brunelle A, Hite M, et al. Usability and tolerability study in human subjects with a novel precision olfactory delivery (Pod)device. Poster M1050 presented at the American Association of Pharmaceutical Scientists Annual Meeting, San Antonio, Texas, Nov 10-14, 2013.
   Google Scholar
• Craig K, Hoekman J, Jeleva M, et al. Cardiovascular profile of dihydroergotamine mesylate (DHE) delivered by INP104 compared to D.H.E. 45® for injection from the INP104-101 clinical trial. Presented at the 2019 American Headache Society Annual Meeting; Pennsylvania Convention Center in Philadelphia; 2019 Jun.
   Google Scholar
• Shrewsbury SB, Jeleva M, Satterly KH, et al. STOP 101: a phase 1, randomized, open-label, comparative bioavailability study of INP104, dihydroergotamine mesylate (DHE) administered intranasally by a I123 precision olfactory delivery (POD®) device, in healthy adult subjects. Headache. 2019;59(3):394–409. doi: 10.1111/head.13476
   PubMed Web of Science ®Google Scholar
• Smith TR, Winner P, Aurora SK, et al. STOP 301: a phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, precision olfactory delivery (POD®) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients. Headache. 2021;61(8):1214–1226. doi: 10.1111/head.14184
   PubMed Web of Science ®Google Scholar
• Lipton RB, Albrecht D, Bermudez M, et al. A randomized, open-label, 5-period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults. Headache. 2024;64(3):266–275. doi: 10.1111/head.14685
   PubMed Web of Science ®Google Scholar
• Starling AJ, Mallick-Searle T, Shrewsbury SB, et al. INP104: a drug evaluation of a nonoral product for the acute treatment of migraine. Pain Manag. 2023;13(5):283–298. doi: 10.2217/pmt-2022-0063
   PubMed Web of Science ®Google Scholar
• Aurora SK, Silberstein SD, Kori SH, et al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache. 2011;51(4):507–517. doi: 10.1111/j.1526-4610.2011.01869.x
   PubMed Web of Science ®Google Scholar